In a groundbreaking study poised to reshape our understanding of Alzheimer’s disease (AD) pathology, scientists have unveiled an intricate cellular dialogue that could herald new therapeutic avenues. For decades, Alzheimer’s disease has baffled researchers with its relentless cognitive decline and complex molecular underpinnings, challenging our ability to devise effective treatments. Now, recent findings from a team of neuroscientists have illuminated a previously underappreciated mechanism involving mitochondrial transfer from microglia to astrocytes via extracellular vesicles enriched with glycoprotein nonmetastatic melanoma protein B (GPNMB). This novel pathway not only sheds light on the cellular interplay critical to neurodegeneration but also offers a promising target for mitigating tau-related neurotoxicity in vivo.
At the core of Alzheimer’s pathology lies the abnormal accumulation of tau protein, which aggregates inside neurons and disrupts their function. The commonly used PS19 mouse model, which carries mutant human tau, recapitulates key aspects of tauopathy and serves as a vital tool for deciphering disease mechanisms. In these PS19 tauopathy mice, microglia—resident immune cells of the brain—were found to engage in a protective cellular exchange by packaging mitochondria into extracellular vesicles (EVs) and delivering them to neighboring astrocytes. Astrocytes, the robust supportive cells critical for maintaining neuronal health, benefit profoundly from acquiring these functional mitochondria, paradoxically receiving aid from the very immune system cells often accused of exacerbating neuroinflammation.
Detailed molecular analyses have revealed that within microglia, tau protein undergoes cleavage to produce distinct N-terminal fragments. These fragments are not bystanders; instead, they assemble into a mitochondrial complex involving Parkin and Nix proteins alongside GPNMB. Parkin and Nix are well-established mediators of mitochondrial quality control and mitophagy, suggesting that this complex acts as a specialized signaling hub to orchestrate mitochondrial handling in microglia. GPNMB—a transmembrane glycoprotein linked to cellular adhesion and inflammation—is the lynchpin that appears to regulate the EV-mediated secretion of mitochondria, ensuring their successful packaging and transfer.
Remarkably, the transfer of functional mitochondria by extracellular vesicles was shown to elevate astrocytic functions. Astrocytes receiving these mitochondrial cargos exhibited enhanced metabolic activity and resilience, translating into better support for synaptic integrity and neuronal networks. This mitochondrial handoff significantly attenuated the cognitive impairments characteristic of the PS19 mice, offering compelling evidence that boosting astrocytic health through this mechanism can reverse key pathological features of tauopathy. Behavioral assessments revealed improvements in memory and learning tasks, corroborating the physiological impact of this intercellular mitochondrial exchange.
The importance of GPNMB was further underscored by experiments employing PS19-CcKO mice, in which GPNMB expression was specifically knocked out in microglia. Loss of GPNMB expression completely abolished mitochondrial EV secretion, effectively severing the mitochondrial support line to astrocytes. Consequently, astrocytic functionalities deteriorated, and these mice exhibited exacerbated cognitive deficits, with a worsened pathological landscape compared to controls. This finding establishes microglial GPNMB as an essential regulator of mitochondrial trafficking in the diseased brain, a role previously unappreciated in the context of neurodegeneration.
This microglia-to-astrocyte mitochondrial transfer paradigm compels a reevaluation of neuroimmune interactions in AD. Traditionally viewed as contributors to neuroinflammation and neuronal damage, microglia now emerge as dynamic players capable of facilitating neuroprotection via organelle donation. The involvement of extracellular vesicles, which have garnered attention as vehicles of intercellular communication in recent years, highlights a sophisticated method of cellular cooperation, extending far beyond traditional neurotransmitter and cytokine signaling.
Importantly, the research uncovered that GPNMB-enriched extracellular vesicles derived from PS19 mice themselves could ameliorate pathological phenotypes when administered to the same tauopathy model. This autologous EV therapy reduced tau pathology, improved cognitive outcomes, and reinvigorated astrocytic function, placing EV-based approaches at the forefront of potential Alzheimer’s interventions. This approach circumvents many challenges associated with direct mitochondrial transplantation, leveraging endogenous vesicle biology to achieve therapeutic benefit.
The translational implications of these findings are profound. By pinpointing the molecular players—namely, GPNMB, Parkin, and Nix—in mitochondrial EV secretion, the study lays the groundwork for developing strategies to enhance mitochondrial transfer or mimic its effects pharmacologically. Targeting GPNMB or modulating the EV release machinery could amplify astrocytic support functions, potentially halting or reversing neurodegenerative processes tied to tauopathy and related dementias.
Furthermore, these results resonate with a broader theme in neurodegeneration: the interdependence of diverse brain cell types and the critical importance of metabolic homeostasis. Astrocytes, traditionally overshadowed by neurons in Alzheimer’s research, are now unveiled as central nodes modulated by microglial activity. The mitochondrial exchanges suggest a form of metabolic coupling that sustains cellular health and counters the energy deficits increasingly observed in AD brains.
While this study spotlights a sophisticated mitochondrial transfer mechanism in a tauopathy mouse model, it opens the door to numerous questions. How universal is this pathway across other neurodegenerative diseases? Do aged human microglia retain this EV-mediated mitochondrial transfer ability? Could peripheral immune cells contribute similarly? Addressing these will be critical for harnessing this mechanism therapeutically and understanding its broader neurological significance.
The current findings also elevate GPNMB from a relatively obscure glycoprotein to a pivotal biomolecule in neurodegeneration, compelling new investigations into its regulation and function across different cell types and pathological contexts. As researchers delve deeper into EV composition and cargo specificity, tailored engineering of vesicles to optimize delivery of healthy mitochondria or other protective molecules may emerge as a viable clinical modality.
Overall, this study reframes the cellular narrative of Alzheimer’s disease by revealing a nuanced, previously hidden exchange of mitochondria that mitigates cognitive decline. It suggests a fresh therapeutic angle where enhancing endogenous cellular crosstalk, rather than solely targeting tau aggregation or amyloid plaques, could transform disease trajectories. This work exemplifies the importance of investigating intercellular cooperation in the brain’s complex cellular ecosystem, opening promising avenues toward meaningful clinical breakthroughs for Alzheimer’s and potentially other neurodegenerative disorders.
In conclusion, the discovery that microglia can donate functional mitochondria to astrocytes through GPNMB-enriched extracellular vesicles marks a significant advance in our understanding of Alzheimer’s disease mechanisms. By demonstrating that this mitochondrial transfer supports astrocytic function and mitigates tau-mediated cognitive deficits, the research offers hope for novel therapeutic strategies that capitalize on natural cellular processes. As the field progresses, translating these insights into human models and ultimately clinical applications will be critical for realizing their full potential in combating this devastating disorder.
Subject of Research: Alzheimer’s disease pathogenesis and cellular interactions involving microglial mitochondrial transfer
Article Title: Microglial mitochondria transfer to astrocytes via GPNMB-enriched extracellular vesicles alleviates cognitive deficits in tauopathy mice
Article References:
Liang, C., Zhou, Y., Zhuang, K. et al. Microglial mitochondria transfer to astrocytes via GPNMB-enriched extracellular vesicles alleviates cognitive deficits in tauopathy mice. Nat Neurosci (2026). https://doi.org/10.1038/s41593-026-02317-w
DOI: https://doi.org/10.1038/s41593-026-02317-w
Tags: Alzheimer’s disease pathologyastrocyte support in neurodegenerationglycoprotein nonmetastatic melanoma protein Bmicroglia-astrocyte interactionmicroglial mitochondria transfermitochondrial transfer via extracellular vesiclesneurodegeneration cellular mechanismsneuroprotective mitochondrial exchangePS19 tauopathy mouse modeltau protein aggregationtauopathy cognitive deficitstherapeutic targets for tau-related neurotoxicity
